Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

84 results
Display

Update on Adjuvant Treatment in Resectable Non-Small Cell Lung Cancer and Potential Biomarkers Predicting Postoperative Relapse

Lim JU

A significant proportion of patients with non-small cell lung cancer (NSCLC) is diagnosed in the early and resectable stage. Despite the use of platinum-based adjuvant chemotherapy, there was only a...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
New Targeted Therapy for Non-Small Cell Lung Cancer

Chung EK, Yong SH, Lee EH, Kim EY, Chang YS, Lee SH

Lung cancer ranks first in cancer mortality in Korea and cancer incidence in Korean men. More than half of Korean lung cancer patients undergo chemotherapy, including adjuvant therapy. Cytotoxic agents,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of MET alteration in EGFR-mutant non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitor from paired biopsy: A retrospective cohort study

Ku BM, Park S, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Choi YL, Ahn MJ

Purpose: Mesenchymal-epithelial transition tyrosine kinase receptor (MET) amplification is one of the common acquired resistance mechanisms to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI). To evaluate the usefulness...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Molecular biomarker testing for non–small cell lung cancer: consensus statement of the Korean Cardiopulmonary Pathology Study Group

Chang S, Shim HS, Kim TJ, Choi YL, Kim WS, Shin DH, Kim L, Park HS, Lee GK, Lee CH, Korean Cardiopulmonary Pathology Study Group

Molecular biomarker testing is the standard of care for non–small cell lung cancer (NSCLC) patients. In 2017, the Korean Cardiopulmonary Pathology Study Group and the Korean Molecular Pathology Study Group...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Feasibility of video-assisted thoracoscopic sleeve lobectomy for non-small cell lung cancer

Jeon YJ, Yun J, Choi YS, Kim MS, Choi JW

Purpose: Sleeve lobectomy is a safe and effective surgical procedure for centrally located non-small cell lung cancer (NSCLC). However, the use of video-assisted thoracoscopic surgery (VATS) on bronchial sleeve resection...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune Checkpoint Inhibitors for Non-Small-Cell Lung Cancer with Brain Metastasis : The Role of Gamma Knife Radiosurgery

Lee MH, Cho KR, Choi JW, Kong DS, Seol HJ, Nam DH, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ, Park K, Lee JI

Objective : Immune checkpoint inhibitors (ICIs) are approved for treating non-small-cell lung cancer (NSCLC); however, the safety and efficacy of combined ICI and Gamma Knife radiosurgery (GKS) treatment remain undefined....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of oncological outcomes of single-port versus multi-port video-assisted thoracoscopic surgery for non-small-cell lung cancer: a propensity-matched analysis

Yoon DW, Choi YS, Sung K, Kim H

Purpose: There are few reports about oncological outcomes of single-port (SP) video-assisted thoracoscopic surgery (VATS) lobectomy, represented by overall survival (OS), disease-free survival (DFS), and adequacy of lymph node retrieval....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Characteristics of Korean Patients with Lung Cancer Who Have Programmed Death-Ligand 1 Expression

Park HY, Oh IJ, Kho BG, Kim TO, Shin HJ, Park CK, Kwon YS, Kim YI, Lim SC, Kim YC, Choi YD

BACKGROUND: Programmed death-ligand 1 (PD-L1), a transmembrane protein, binds to the programmed death-1 (PD-1) receptor, and anti-PD-1 therapy enables immune responses against tumors. This study aimed to assess clinical characteristics...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

Choi JH, Choi J, Chung SM, Oh JY, Lee YS, Min KH, Hur GY, Shim JJ, Kang KH, Lee HK, Lee SY

BACKGROUND: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Morphologic Evaluation of Primary Non-Small Cell Lung Cancer by 3 Tesla MRI with Free-Breathing Ultrashort Echo Time and Radial T1-Weighted Gradient Echo Sequences: A Comparison with CT Analysis

Lee H, Choi E, Lee MK, Zhang Y, Kwon W

PURPOSE: To evaluate morphologic features of primary non-small cell lung cancer using 3 Tesla MRI with free-breathing compared with CT. MATERIALS AND METHODS: Thirty-six patients were enrolled. A 64-channel multidetector CT...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Provisional Guideline Recommendation for EGFR Gene Mutation Testing in Liquid Samples of Lung Cancer Patients: A Proposal by the Korean Cardiopulmonary Pathology Study Group

Shin DH, Shim HS, Kim TJ, Park HS, Choi YL, Kim WS, Kim L, Chang SH, Song JS, Kim HJ, Han JH, Lee CH, Lee GK, Jang SJ, Korean Cardiopulmonary Pathology Study Group

Liquid biopsy for detection of mutation from circulating tumor DNA is a new technology which is attractive in that it is non-invasive. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic role of beclin-1 in locally advanced non-small cell lung cancer in patients receiving docetaxel-platinum induction chemotherapy

Lee HY, Shin JH, Lee KY, Park JK, Sung SW, Kim YS, Kang JH, Kim JO

BACKGROUND/AIMS: The outcome of local treatment for advanced non-small cell lung cancer (NSCLC) remains poor, with therapies such as induction chemotherapy (IC) yielding conflicting results. This study aimed to assess...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Current status of immune checkpoint inhibitors in treatment of non-small cell lung cancer

Lim SW, Ahn MJ

Lung cancer remains a leading cause of cancer mortality worldwide, including in Korea. Systemic therapy including platinum-based chemotherapy and targeted therapy should be provided to patients with stage IV non-small...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Pulmonary Subsolid Nodules: An Overview & Management Guidelines

Song YS, Park CM

Pulmonary subsolid nodules (SSNs) refer to the pulmonary pure ground-glass nodules and part-solid nodules. SSNs are frequently encountered in clinical settings, such as in screenings conducted with chest computed tomography....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer

Jung CY, Antonia SJ

Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC)...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Invasive pulmonary aspergillosis in a patient with metastatic non-small cell lung cancer after treatment with gefitinib

Park S, Park S, Choi H, Park JY, Lim HS, Park MJ, Kim SY

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Epidermal growth factor receptor mutation and pattern of brain metastasis in patients with non-small cell lung cancer

Baek MY, Ahn HK, Park KR, Park HS, Kang SM, Park I, Kim YS, Hong J, Sym SJ, Park J, Lee JH, Shin DB, Cho EK

BACKGROUND/AIMS: We investigated the time taken for patients with metastatic non-small cell lung cancer (NSCLC) to develop brain metastases (BM), as well as their subsequent overall median survival following diagnosis,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Systemic Sclerosis Associated with Non-small Cell Lung Cancer and Papillary Thyroid Cancer: Case Report and Literature Review

Kim HJ, Kim JJ, Park HJ, Kim YT

We report the case of a 52-year-old patient with rheumatic vascular disease (systemic sclerosis), non-small cell lung cancer, and papillary thyroid cancer. Malignant tumors have been described in 3-11% of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
KRAS G₁₂C mutation as a poor prognostic marker of pemetrexed treatment in non-small cell lung cancer

Park S, Kim JY, Lee SH, Suh B, Keam B, Kim TM, Kim DW, Heo DS

BACKGROUND/AIMS: The predictive and prognostic value of KRAS mutation and its type of mutations in non-small cell lung cancer (NSCLC) are controversial. This clinical study was designed to investigate the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?

Choi YW, Choi JH

An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr